Cargando…

COVID-19: Coronavirus Vaccine Development Updates

Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jing, Zhao, Shan, Ou, Junxian, Zhang, Jing, Lan, Wendong, Guan, Wenyi, Wu, Xiaowei, Yan, Yuqian, Zhao, Wei, Wu, Jianguo, Chodosh, James, Zhang, Qiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785583/
https://www.ncbi.nlm.nih.gov/pubmed/33424848
http://dx.doi.org/10.3389/fimmu.2020.602256
_version_ 1783632472961974272
author Zhao, Jing
Zhao, Shan
Ou, Junxian
Zhang, Jing
Lan, Wendong
Guan, Wenyi
Wu, Xiaowei
Yan, Yuqian
Zhao, Wei
Wu, Jianguo
Chodosh, James
Zhang, Qiwei
author_facet Zhao, Jing
Zhao, Shan
Ou, Junxian
Zhang, Jing
Lan, Wendong
Guan, Wenyi
Wu, Xiaowei
Yan, Yuqian
Zhao, Wei
Wu, Jianguo
Chodosh, James
Zhang, Qiwei
author_sort Zhao, Jing
collection PubMed
description Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, Betacoronavirus, this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development.
format Online
Article
Text
id pubmed-7785583
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77855832021-01-07 COVID-19: Coronavirus Vaccine Development Updates Zhao, Jing Zhao, Shan Ou, Junxian Zhang, Jing Lan, Wendong Guan, Wenyi Wu, Xiaowei Yan, Yuqian Zhao, Wei Wu, Jianguo Chodosh, James Zhang, Qiwei Front Immunol Immunology Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, Betacoronavirus, this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development. Frontiers Media S.A. 2020-12-23 /pmc/articles/PMC7785583/ /pubmed/33424848 http://dx.doi.org/10.3389/fimmu.2020.602256 Text en Copyright © 2020 Zhao, Zhao, Ou, Zhang, Lan, Guan, Wu, Yan, Zhao, Wu, Chodosh and Zhang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhao, Jing
Zhao, Shan
Ou, Junxian
Zhang, Jing
Lan, Wendong
Guan, Wenyi
Wu, Xiaowei
Yan, Yuqian
Zhao, Wei
Wu, Jianguo
Chodosh, James
Zhang, Qiwei
COVID-19: Coronavirus Vaccine Development Updates
title COVID-19: Coronavirus Vaccine Development Updates
title_full COVID-19: Coronavirus Vaccine Development Updates
title_fullStr COVID-19: Coronavirus Vaccine Development Updates
title_full_unstemmed COVID-19: Coronavirus Vaccine Development Updates
title_short COVID-19: Coronavirus Vaccine Development Updates
title_sort covid-19: coronavirus vaccine development updates
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785583/
https://www.ncbi.nlm.nih.gov/pubmed/33424848
http://dx.doi.org/10.3389/fimmu.2020.602256
work_keys_str_mv AT zhaojing covid19coronavirusvaccinedevelopmentupdates
AT zhaoshan covid19coronavirusvaccinedevelopmentupdates
AT oujunxian covid19coronavirusvaccinedevelopmentupdates
AT zhangjing covid19coronavirusvaccinedevelopmentupdates
AT lanwendong covid19coronavirusvaccinedevelopmentupdates
AT guanwenyi covid19coronavirusvaccinedevelopmentupdates
AT wuxiaowei covid19coronavirusvaccinedevelopmentupdates
AT yanyuqian covid19coronavirusvaccinedevelopmentupdates
AT zhaowei covid19coronavirusvaccinedevelopmentupdates
AT wujianguo covid19coronavirusvaccinedevelopmentupdates
AT chodoshjames covid19coronavirusvaccinedevelopmentupdates
AT zhangqiwei covid19coronavirusvaccinedevelopmentupdates